BackCoeptis Therapeutics Holdings- Warrants (31/10/2025) Overview

Coeptis Therapeutics Holdings- Warrants (31/10/2025) Net Tangible Assets

Coeptis Therapeutics Holdings- Warrants (31/10/2025)'s net tangible assets is $130M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$132.48M
1771.20% YoYΔ $125.40M vs prior year quarter

Peer trimmed avg / median

Loading

Coeptis Therapeutics Holdings- Warrants (31/10/2025) Net Tangible Assets History

Loading

Coeptis Therapeutics Holdings- Warrants (31/10/2025) vs. peers: Net Tangible Assets Comparison

Loading

Coeptis Therapeutics Holdings- Warrants (31/10/2025) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Coeptis Therapeutics Holdings- Warrants (31/10/2025) (COEPW) FAQ

The latest net tangible assets for COEPW is $130M as of June 2026. That compares with $7.1M in the prior-year period — up 1771.2% year over year. Investors often review this figure alongside Coeptis Therapeutics Holdings- Warrants (31/10/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, COEPW's net tangible assets moved from $7.1M to $130M — a 1771.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Coeptis Therapeutics Holdings- Warrants (31/10/2025)'s operating scale or balance-sheet position.

A net tangible assets figure of $130M for COEPW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting COEPW's net tangible assets ($130M), review year-over-year change from $7.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.